HRP20200636T1 - Indukcija male molekule trail genoma u normalnim i tumorskim stanicama kao antikancerogena terapija - Google Patents
Indukcija male molekule trail genoma u normalnim i tumorskim stanicama kao antikancerogena terapija Download PDFInfo
- Publication number
- HRP20200636T1 HRP20200636T1 HRP20200636TT HRP20200636T HRP20200636T1 HR P20200636 T1 HRP20200636 T1 HR P20200636T1 HR P20200636T T HRP20200636T T HR P20200636TT HR P20200636 T HRP20200636 T HR P20200636T HR P20200636 T1 HRP20200636 T1 HR P20200636T1
- Authority
- HR
- Croatia
- Prior art keywords
- preparation
- use according
- cancer
- group
- therapeutic agent
- Prior art date
Links
- 101100369993 Mus musculus Tnfsf10 gene Proteins 0.000 title 1
- 238000011319 anticancer therapy Methods 0.000 title 1
- 230000006698 induction Effects 0.000 title 1
- 150000003384 small molecules Chemical class 0.000 title 1
- 210000004881 tumor cell Anatomy 0.000 title 1
- 238000000034 method Methods 0.000 claims 5
- 239000000825 pharmaceutical preparation Substances 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 239000002246 antineoplastic agent Substances 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 239000012472 biological sample Substances 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims 1
- 229940121849 Mitotic inhibitor Drugs 0.000 claims 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 1
- 230000001772 anti-angiogenic effect Effects 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 229960000397 bevacizumab Drugs 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 229960003668 docetaxel Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 238000001361 intraarterial administration Methods 0.000 claims 1
- 238000000185 intracerebroventricular administration Methods 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000007913 intrathecal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- 210000002381 plasma Anatomy 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- RSAQARAFWMUYLL-UHFFFAOYSA-N tic-10 Chemical compound CC1=CC=CC=C1CN1C(CCN(CC=2C=CC=CC=2)C2)=C2C(=O)N2CCN=C21 RSAQARAFWMUYLL-UHFFFAOYSA-N 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Claims (12)
1. Farmaceutski pripravak u postupku liječenja karcinoma, koji sadrži spoj NSC350625, ili njegovu farmaceutski prihvatljivu sol; i farmaceutski prihvatljiv nosač.
2. Pripravak za primjenu sukladno zahtjevu 1, pri čemu karcinom predstavlja karcinom mozga.
3. Farmaceutski pripravak za primjenu sukladno zahtjevu 1, pri čemu je karcinom odabran iz skupine koja se sastoji od karcinoma debelog crijeva, karcinoma dojke, glioblastoma multiforme, i kolorektalnog karcinoma.
4. Farmaceutski pripravak za primjenu sukladno zahtjevu 1, pri čemu postupak nadalje sadrži primjenu drugog terapijskog sredstva na subjekt, pri čemu drugo terapijsko sredstvo sadrži sredstvo protiv karcinoma.
5. Farmaceutski pripravak za primjenu sukladno zahtjevu 1, pri čemu postupak dalje sadrži primjenu drugog terapijskog sredstva na subjekt, pri čemu drugi terapeutik sadrži antiangiogen.
6. Farmaceutski pripravak za primjenu sukladno zahtjevu 4, pri čemu je protukarcinomsko sredstvo mitotički inhibitor.
7. Pripravak za primjenu sukladno zahtjevu 4, pri čemu je protukarcinomsko sredstvo odabran iz skupine sastavljene od paklitaksela, docetaksela i njihove kombinacije.
8. Pripravak za primjenu sukladno zahtjevu 5, pri čemu je antiangiogen bevacizumab.
9. Pripravak za primjenu sukladno zahtjevu 1, pri čemu se pripravak daje oralno.
10. Pripravak za primjenu sukladno zahtjevu 1, pri čemu se pripravak daje načinom odabran iz skupine koja se sastoji od rektalnog, nazalnog, pulmonarnog, epiduralnog, okularnog, otičkog, intraarterijskog, intrakardijalnog, intracerebroventrikularnog, intradermalnog, intravenskog, intramuskularnog, intraperitonealnog, intrakoštanog, intratekalnog, intravezikalnog, subkutanog, topikalnog, transdermalnog, transmukoznog, sublingvalnog, bukalnog, vaginalnog, i inhalativnog načina primjene.
11. Pripravak za primjenu sukladno zahtjevu 1, pri čemu postupak nadalje sadrži procjenu učinkovitosti liječenja, pri čemu procjena učinkovitosti liječenja sadrži testiranje TNF-srodnog liganda koji inducira apoptozu u biološkom uzorku dobivenom od subjekta.
12. Pripravak za primjenu u je biološki uzorak odabran iz skupine koja se sastoji od krvi, seruma, plazme i cerebrospinalne tekućine.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161480743P | 2011-04-29 | 2011-04-29 | |
EP12776073.4A EP2701708B1 (en) | 2011-04-29 | 2012-04-30 | Small molecule trail gene induction by normal and tumor cells as an anticancer therapy |
PCT/US2012/035831 WO2012149546A2 (en) | 2011-04-29 | 2012-04-30 | Small molecule trail gene induction by normal and tumor cells as an anticancer therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20200636T1 true HRP20200636T1 (hr) | 2020-07-10 |
Family
ID=47068061
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20200636TT HRP20200636T1 (hr) | 2011-04-29 | 2020-04-21 | Indukcija male molekule trail genoma u normalnim i tumorskim stanicama kao antikancerogena terapija |
Country Status (16)
Country | Link |
---|---|
US (8) | US8673923B2 (hr) |
EP (3) | EP3679934A1 (hr) |
JP (6) | JP6132833B2 (hr) |
CA (1) | CA2832342C (hr) |
CY (1) | CY1123010T1 (hr) |
DK (1) | DK2701708T3 (hr) |
ES (1) | ES2786033T3 (hr) |
HR (1) | HRP20200636T1 (hr) |
HU (1) | HUE049207T2 (hr) |
LT (1) | LT2701708T (hr) |
MX (2) | MX365365B (hr) |
PL (1) | PL2701708T3 (hr) |
PT (1) | PT2701708T (hr) |
RS (1) | RS60186B1 (hr) |
SI (1) | SI2701708T1 (hr) |
WO (1) | WO2012149546A2 (hr) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012149546A2 (en) | 2011-04-29 | 2012-11-01 | The Penn State Research Foundation | Small molecule trail gene induction by normal and tumor cells as an anticancer therapy |
US10813630B2 (en) | 2011-08-09 | 2020-10-27 | Corquest Medical, Inc. | Closure system for atrial wall |
US10307167B2 (en) | 2012-12-14 | 2019-06-04 | Corquest Medical, Inc. | Assembly and method for left atrial appendage occlusion |
US10314594B2 (en) | 2012-12-14 | 2019-06-11 | Corquest Medical, Inc. | Assembly and method for left atrial appendage occlusion |
US20140142689A1 (en) | 2012-11-21 | 2014-05-22 | Didier De Canniere | Device and method of treating heart valve malfunction |
HUE044238T2 (hu) * | 2013-03-13 | 2019-10-28 | Oncoceutics Inc | 7-benzil-10-(2-metilbenzil)-2,6,7,8,9,10-hexahidroimidazo[l,2-a]pirido[4,3-d]pirimidin-5(3h)-on rák kezelésénél történõ alkalmazásra |
US9376437B2 (en) | 2013-03-13 | 2016-06-28 | Oncoceutics, Inc | 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy |
WO2015073072A1 (en) * | 2013-11-15 | 2015-05-21 | Oncoceutics, Inc. | 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one |
US9688679B2 (en) | 2013-03-13 | 2017-06-27 | Oncoceutics, Inc. | 7-benzyl-4-(methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-A]pyrido[3,4-E]pyrimidin-5 (1H)-one, salts thereof and methods of using the same in combination therapy |
DK3546461T3 (da) * | 2013-11-15 | 2021-09-13 | Oncoceutics Inc | 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one, salts thereof and methods of using the same in combination therapy |
US9566443B2 (en) | 2013-11-26 | 2017-02-14 | Corquest Medical, Inc. | System for treating heart valve malfunction including mitral regurgitation |
WO2015138638A1 (en) | 2014-03-11 | 2015-09-17 | Theraly Pharmaceuticals, Inc. | Long acting trail receptor agonists for treatment of autoimmune diseases |
RS60163B1 (sr) | 2014-03-31 | 2020-05-29 | Scripps Research Inst | Farmakofor koji indukuje trail |
US10842626B2 (en) | 2014-12-09 | 2020-11-24 | Didier De Canniere | Intracardiac device to correct mitral regurgitation |
MX2017009841A (es) | 2015-01-30 | 2018-02-09 | Oncoceutics Inc | 7-bencil-4-(2-metilbencilo) -2,4,6,7,8,9-hexahidroimidazo [1,2-a] pirido [3,4-e] pirimidin-5 (1h) -ona, analogos y sales del mismo y su uso en terapia. |
WO2016160918A1 (en) | 2015-03-31 | 2016-10-06 | The University Of North Carolina At Chapel Hill | Delivery vehicles for stem cells and uses thereof |
CN104860948B (zh) * | 2015-05-15 | 2017-09-26 | 南京盖特医药技术有限公司 | 咪唑并嘧啶酮类化合物及其制备方法和应用 |
WO2017106627A1 (en) | 2015-12-17 | 2017-06-22 | The Johns Hopkins University | Ameliorating systemic sclerosis with death receptor agonists |
NZ745425A (en) | 2016-01-29 | 2023-03-31 | Oncoceutics Inc | G protein-coupled receptor (gpcr) modulation by imipridones |
WO2017177148A1 (en) | 2016-04-07 | 2017-10-12 | The Johns Hopkins University | Compositions and methods for treating pancreatitis and pain with death receptor agonists |
US10172862B2 (en) | 2017-01-30 | 2019-01-08 | Oncoceutics, Inc. | Imipridones for gliomas |
US11767353B2 (en) | 2020-06-05 | 2023-09-26 | Theraly Fibrosis, Inc. | Trail compositions with reduced immunogenicity |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA105008A (en) | 1907-02-06 | 1907-04-30 | Charles B. Grimshaw | Self-closing valve |
DE2150062A1 (de) | 1971-10-07 | 1973-04-12 | Boehringer Sohn Ingelheim | Imidazo- eckige klammer auf 1,2-a eckige klammer zu -pyrido- eckige klammer auf 4,3-d eckige klammer zu -pyrimidine, deren saeureadditionssalze und verfahren zu deren herstellung |
GB9407386D0 (en) | 1994-04-14 | 1994-06-08 | Smithkline Beecham Plc | Pharmaceutical formulation |
US5648097A (en) | 1995-10-04 | 1997-07-15 | Biotek, Inc. | Calcium mineral-based microparticles and method for the production thereof |
US6391336B1 (en) | 1997-09-22 | 2002-05-21 | Royer Biomedical, Inc. | Inorganic-polymer complexes for the controlled release of compounds including medicinals |
ES2357225T3 (es) | 2001-11-01 | 2011-04-20 | Uab Research Foundation | Combinaciones de anticuerpos anti-dr5 y anticuerpos anti-dr4 y otros agentes terapéuticos. |
AU2002367172A1 (en) | 2001-12-21 | 2003-07-15 | Bayer Pharmaceuticals Corporation | 2,4-diamino-pyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents |
RU2008129028A (ru) * | 2005-12-16 | 2010-01-27 | Дженентек, Инк. (Us) | Способ диагностики, прогнозировния и лечения глиомы |
US8084027B2 (en) * | 2006-02-10 | 2011-12-27 | Nerviano Medical Sciences S.R.L. | Combinations comprising a CDK inhibitor and a growth factor antibody or anti-mitotic |
EP2037919A2 (en) | 2006-06-30 | 2009-03-25 | Schering Corporation | Method of using substituted piperidines that increase p53 activity |
CN102105148B (zh) * | 2008-07-24 | 2013-04-10 | 内尔维阿诺医学科学有限公司 | 包含aurora激酶抑制剂和抗肿瘤药的治疗组合 |
EP2349323A2 (en) * | 2009-06-24 | 2011-08-03 | Stephen Evans-Freke | Methods of using corticotropin-releasing factor for the treatment of cancer |
WO2012149546A2 (en) | 2011-04-29 | 2012-11-01 | The Penn State Research Foundation | Small molecule trail gene induction by normal and tumor cells as an anticancer therapy |
HUE044238T2 (hu) | 2013-03-13 | 2019-10-28 | Oncoceutics Inc | 7-benzil-10-(2-metilbenzil)-2,6,7,8,9,10-hexahidroimidazo[l,2-a]pirido[4,3-d]pirimidin-5(3h)-on rák kezelésénél történõ alkalmazásra |
-
2012
- 2012-04-30 WO PCT/US2012/035831 patent/WO2012149546A2/en active Application Filing
- 2012-04-30 SI SI201231766T patent/SI2701708T1/sl unknown
- 2012-04-30 CA CA2832342A patent/CA2832342C/en active Active
- 2012-04-30 DK DK12776073.4T patent/DK2701708T3/da active
- 2012-04-30 LT LTEP12776073.4T patent/LT2701708T/lt unknown
- 2012-04-30 JP JP2014508181A patent/JP6132833B2/ja active Active
- 2012-04-30 EP EP20152317.2A patent/EP3679934A1/en active Pending
- 2012-04-30 MX MX2013012346A patent/MX365365B/es active IP Right Grant
- 2012-04-30 EP EP12776073.4A patent/EP2701708B1/en active Active
- 2012-04-30 PT PT127760734T patent/PT2701708T/pt unknown
- 2012-04-30 HU HUE12776073A patent/HUE049207T2/hu unknown
- 2012-04-30 EP EP23206770.2A patent/EP4335511A3/en active Pending
- 2012-04-30 PL PL12776073T patent/PL2701708T3/pl unknown
- 2012-04-30 RS RS20200454A patent/RS60186B1/sr unknown
- 2012-04-30 US US13/459,775 patent/US8673923B2/en not_active Ceased
- 2012-04-30 ES ES12776073T patent/ES2786033T3/es active Active
-
2013
- 2013-10-22 MX MX2019006379A patent/MX2019006379A/es unknown
-
2014
- 2014-02-27 US US14/192,329 patent/US9061032B2/en active Active
- 2014-07-22 US US14/338,055 patent/US9072744B1/en active Active
-
2015
- 2015-06-08 US US14/733,740 patent/US9452165B2/en active Active
- 2015-09-17 US US14/857,418 patent/USRE46290E1/en active Active
-
2016
- 2016-07-20 JP JP2016142086A patent/JP2016199580A/ja not_active Withdrawn
- 2016-09-19 US US15/269,114 patent/US9629842B2/en active Active
-
2017
- 2017-04-23 US US15/494,515 patent/US20170224690A1/en not_active Abandoned
-
2018
- 2018-11-08 JP JP2018210558A patent/JP2019019145A/ja not_active Withdrawn
-
2020
- 2020-04-14 CY CY20201100350T patent/CY1123010T1/el unknown
- 2020-04-21 HR HRP20200636TT patent/HRP20200636T1/hr unknown
-
2021
- 2021-09-16 JP JP2021151110A patent/JP2021185210A/ja active Pending
-
2022
- 2022-03-21 US US17/655,646 patent/US20220288079A1/en active Pending
-
2023
- 2023-03-06 JP JP2023033777A patent/JP2023060196A/ja active Pending
-
2024
- 2024-02-27 JP JP2024027432A patent/JP2024051080A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20200636T1 (hr) | Indukcija male molekule trail genoma u normalnim i tumorskim stanicama kao antikancerogena terapija | |
Li et al. | Erlotinib-induced autophagy in epidermal growth factor receptor mutated non-small cell lung cancer | |
Selvi et al. | Neferine augments therapeutic efficacy of cisplatin through ROS-mediated non-canonical autophagy in human lung adenocarcinoma (A549 cells) | |
CO6781534A2 (es) | Sales de 2,3-dihidroimidazol[1,2-c]quinazolina substituida | |
Yin et al. | In vitro and in vivo evaluation of the antitumor efficiency of resveratrol against lung cancer | |
RU2014119150A (ru) | Модулирование некоторых тирозинкиназ | |
TR201807411T4 (tr) | DNA-PK inhibitörleri. | |
JP2018513104A5 (hr) | ||
RU2013148728A (ru) | Комбинации соединений, ингибирующих акт, и эрлотиниба и способы их применения | |
JP2014512354A5 (hr) | ||
JO3419B1 (ar) | مركبات بيريدوبيرازين مضادة للسرطان من خلال تثبيط إنزيمات كيناز fgfr | |
JP2011503071A5 (ja) | ヨードニトロベンズアミド化合物と抗腫瘍剤の組み合わせによる卵巣がんの治療 | |
JP2010180210A5 (hr) | ||
MX356205B (es) | Benzopirazinas anticancerigenas via la inhibicion de cinasas del receptor del factor de crecimiento de fibroblasto (fgfr). | |
JP2015512398A5 (hr) | ||
Sun et al. | Inhibition of angiogenesis involves in anticancer activity of riccardin D, a macrocyclic bisbibenzyl, in human lung carcinoma | |
Xie et al. | The cyclin-dependent kinase inhibitor SNS-032 induces apoptosis in breast cancer cells via depletion of Mcl-1 and X-linked inhibitor of apoptosis protein and displays antitumor activity in vivo | |
Huang et al. | miR-126: A novel regulator in colon cancer | |
Ma et al. | miRNA-223 is an anticancer gene in human non-small cell lung cancer through the PI3K/AKT pathway by targeting EGFR | |
PE20141909A1 (es) | Terapia combinada para el tratamiento del cancer de ovario | |
Liu et al. | Rapamycin promotes the anticancer action of dihydroartemisinin in breast cancer MDA-MB-231 cells by regulating expression of Atg7 and DAPK | |
Tang et al. | Combination of baicalein and 10-hydroxy camptothecin exerts remarkable synergetic anti-cancer effects | |
JP2013544892A5 (hr) | ||
JP2014530181A5 (hr) | ||
NI201100192A (es) | Combinación antitumoral que compprende cabazitaxel y capecitabina |